Bio-Techne Analyst Price Targets

Wall Street analyst price targets and consensus rating for Bio-Techne (TECH).

Price Target Range — 12 Quarters

Analyst Consensus — 12 Analysts

3Buy

9Hold

Consensus RatingBuy# Analysts12Avg. Consensus PT$72Upside to Avg. PT-0.7%

Rating Trend — Last 9 Months

Recent Analyst Actions

모든 평가 보기 →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	Wells Fargo	Evan Stampler	Downgrade	Overweight→Equal-Weight	$62→$73
Jul 9, 2026	RBC Capital	Dan Leonard	Downgrade	Outperform→Sector Perform	$62→$73
Jun 30, 2026	TD Cowen	Kyle Boucher	Downgrade	Buy→Hold	$65→$73
Jun 30, 2026	Benchmark	Robert Wasserman	Downgrade	Buy→Hold	—
Jun 29, 2026	Citigroup	Patrick Donnelly	Downgrade	Buy→Neutral	$70→$73
Jun 26, 2026	Stephens & Co.	Steven Etoch	Downgrade	Overweight→Equal-Weight	$68→$73
Jun 26, 2026	William Blair	Matt Larew	Downgrade	Outperform→Market Perform	—
Jun 26, 2026	Baird	Catherine Schulte	PT Raise	Neutral	$49→$73
Jun 11, 2026	Piper Sandler	David Westenberg	Initiate	Neutral	$65
May 15, 2026	RBC Capital	Dan Leonard	Reinstates	Outperform	$62
May 7, 2026	Citigroup	Patrick Donnelly	PT Cut	Buy	$80→$70
May 7, 2026	Wells Fargo	Brandon Couillard	PT Cut	Overweight	$76→$62
May 7, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	In-Line	$54→$50
Apr 6, 2026	Evercore ISI Group	Daniel Markowitz	PT Cut	In-Line	$68→$54
Feb 6, 2026	Wells Fargo	Brandon Couillard	PT Raise	Overweight	$70→$76
Feb 5, 2026	Citigroup	Patrick Donnelly	PT Raise	Buy	$70→$80
Feb 5, 2026	Stifel	Daniel Arias	PT Raise	Hold	$60→$65
Feb 5, 2026	TD Cowen	Kyle Boucher	PT Raise	Buy	$70→$80
Feb 5, 2026	UBS	Dan Leonard	PT Raise	Buy	$70→$79
Feb 5, 2026	Evercore ISI Group	Daniel Markowitz	PT Raise	In-Line	$62→$68

Analyst Ratings News

PRO
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

Wells Fargo analyst Brandon Couillard downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $62 to $73.

Benzinga Newsdesk

PRO
RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

RBC Capital analyst Dan Leonard downgrades Bio-Techne (NASDAQ:TECH) from Outperform to Sector Perform and raises the price target from $62 to $73.

Benzinga Newsdesk

PRO
TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73

TD Cowen analyst Kyle Boucher downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold and raises the price target from $65 to $73.

Benzinga Newsdesk

PRO
Benchmark Downgrades Bio-Techne to Hold

Benchmark analyst Robert Wasserman downgrades Bio-Techne (NASDAQ:TECH) from Buy to Hold.

Benzinga Newsdesk

PRO
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

Citigroup analyst Patrick Donnelly downgrades Bio-Techne (NASDAQ:TECH) from Buy to Neutral and raises the price target from $70 to $73.

Benzinga Newsdesk

PRO
Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

Stephens & Co. analyst Steven Etoch downgrades Bio-Techne (NASDAQ:TECH) from Overweight to Equal-Weight and raises the price target from $68 to $73.

Benzinga Newsdesk

Bio-Techne Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Bio-Techne Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

PRO
RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

PRO
TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73

PRO
Benchmark Downgrades Bio-Techne to Hold

PRO
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

PRO
Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

People Also Watch

People Also Watch

Bio-Techne Corp

뉴스

파트너 / 기고자

벤징가 글로벌

Bio-Techne Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PROWells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

PRORBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

PROTD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73

PROBenchmark Downgrades Bio-Techne to Hold

PROCitigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

PROStephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

People Also Watch

People Also Watch

PRO
Wells Fargo Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73

PRO
RBC Capital Downgrades Bio-Techne to Sector Perform, Raises Price Target to $73

PRO
TD Cowen Downgrades Bio-Techne to Hold, Raises Price Target to $73

PRO
Benchmark Downgrades Bio-Techne to Hold

PRO
Citigroup Downgrades Bio-Techne to Neutral, Raises Price Target to $73

PRO
Stephens & Co. Downgrades Bio-Techne to Equal-Weight, Raises Price Target to $73